| Literature DB >> 34907103 |
Sunyoung Ahn1, Hyun-Ki Kim2, Woochang Lee3, Sail Chun3, Won-Ki Min3.
Abstract
BACKGROUND: We established high-sensitivity cardiac troponin I (hsTnI) 99th percentile upper reference limits (URLs) for the Centaur XPT High-Sensitivity Troponin I assay (Centaur hsTnI; Siemens, Erlangen, Germany) and Atellica IM High-Sensitivity Troponin I assay (Atellica hsTnI; Siemens) and assessed the effect of outlier elimination.Entities:
Keywords: ADVIA Centaur XPT High-Sensitivity Troponin I assay; Atellica IM High-Sensitivity Troponin I assay; Korean; Ninety-ninth percentile; Outlier; Upper reference limit
Mesh:
Substances:
Year: 2022 PMID: 34907103 PMCID: PMC8677476 DOI: 10.3343/alm.2022.42.3.331
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Fig. 1Flow diagram showing the reference population used, process of outlier elimination, and the final 99th percentile URLs calculated for Centaur hsTnI and Atellica hsTnI.
Abbreviations: eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; HbA1c, hemoglobin A1c; NT-proBNP, N-terminal pro-B-type natriuretic peptide; URL, upper reference limit; hsTnI, high-sensitivity troponin I; IQR, interquartile range.
Fig. 2Distribution of TnI values in the reference population, which was selected according to the strict selection criteria suggested by Sandoval, et al. [10], without outlier elimination. Arrows indicate subjects with outlying TnI values according to Tukey’s 3-IQR method. (A) Men, (B) women.
Abbreviations: TnI, troponin I; IQR, interquartile range.
Fig. 3Distribution of hsTnI values in men and women according to age and sex. The box indicates the 25th and 75th percentiles; the black line corresponds to the median value. (A) Centaur hsTnI, (B) Atellica hsTnI.
Abbreviation: hsTnI, high-sensitivity troponin I.
Fig. 4hsTnI values in four subpopulations according to sex and age (≤55 or >55 years). The box indicates the 25th and 75th percentiles, and the horizontal black line corresponds to the median value. The differences among the groups were statistically significant (P<0.001, Kruskal–Wallis test), with increasing tendencies in the following order: (A) Centaur hsTnI, ≤55 years, women (2.5, 2.5–3.1), all ages, women (3.2, 2.5–4.5), ≤55 years, men (3.7, 2.8–4.7), >55 years, women (3.7, 2.8–5.6), all ages, men (4.2, 3.3–5.7), >55 years, men (4.6, 3.6–6.2) (B) Atellica hsTnI, ≤55 years, women (2.5, 2.5–3.3), all ages, women (3.5, 2.5–4.7), ≤55 years, men (3.9, 3.1–5.1), >55 years, women (4.0, 3.3–6.0), all ages, men (4.2, 3.3–5.9), and >55 years, men (4.9, 3.7–6.6). Data are expressed as (median, IQR) ng/L.
Abbreviations: hsTnI, high-sensitivity troponin I; IQR, interquartile range.
hsTnI 99th percentile URLs according to sex, age group, and before and after outlier elimination.
| Age group | Sex | N | N and % of subjects eliminated | Centaur hsTnI 99th percentile URL | N | N and % of subjects eliminated | Atellica hsTnI 99th percentile URL |
|---|---|---|---|---|---|---|---|
| hsTnI 99th percentile URLs before outlier elimination | |||||||
| All ages | Male | 380 | N/A | 74.7 (47.5–117.9) | 380 | N/A | 75.2 (47.3–122.7) |
| Female | 387 | N/A | 57.5 (41.7–101.1) | 387 | N/A | 55.1 (38.2–95.8) | |
| All | 767 | N/A | 60.4 (445.7–94.8) | 767 | N/A | 59.6 (44.7–96.9) | |
| ≤ 55 yr | Male | 182 | N/A | 114.5 (65.9–256.1) | 182 | N/A | 114.1 (64.7–256.1) |
| Female | 158 | N/A | 64.8 (52.1–71.1) | 158 | N/A | 62.3 (50.3–69.1) | |
| All | 340 | N/A | 66.7 (31.2–186.2) | 340 | N/A | 66.1 (30.3–185.9) | |
| > 55 yr | Male | 198 | N/A | 72.6 (54.0–116.7) | 198 | N/A | 73.4 (54.8–122.5) |
| Female | 229 | N/A | 97.1 (53.6–187.6) | 229 | N/A | 89.0 (51.2–177.0) | |
| All | 427 | N/A | 66.5 (50.1–116.7) | 427 | N/A | 67.0 (49.9–122.7) | |
| hsTnI 99th percentile URLs after outlier elimination | |||||||
| All ages | Male | 349 | 31 (8.2%) | 15.3 (14.7–15.6) | 352 | 28 (7.4%) | 15.5 (15.5–16.0) |
| Female | 357 | 30 (7.6%) | 11.9 (11.1–12.4) | 357 | 30 (7.6%) | 12.9 (11.4–13.2) | |
| All | 706 | 61 (8.0%) | 13.5 (12.8–13.6) | 709 | 58 (7.6%) | 13.4 (12.8–13.8) | |
| ≤ 55 yr | Male | 166 | 16 (8.6%) | 11.9 (10.8–12.0) | 169 | 13 (7.1%) | 11.8 (10.7–12.4) |
| Female | 142 | 16 (10.1%) | 7.0 (6.8–7.0) | 142 | 16 (9.5%) | 7.5 (7.3–7.5) | |
| All | 308 | 32 (9.4%) | 10.3 (9.6–10.5) | 311 | 28 (8.2%) | 10.5 (9.9–11.4) | |
| > 55 yr | Male | 183 | 15 (7.6%) | 16.9 (16.4–18.6) | 183 | 15 (7.6%) | 17.4 (17.0–17.6) |
| Female | 215 | 14 (6.1%) | 13.6 (12.8–13.8) | 215 | 14 (6.6%) | 13.6 (12.9–14.8) | |
| All | 398 | 29 (6.8%) | 16.2 (14.8–16.5) | 397 | 30 (7.0%) | 16.7 (15.2–17.6) | |
Outliers were eliminated using a non-parametric (Tukey’s 3-IQR) method as detailed in the Methods section. The values are presented as median (95% CI) ng/L.
Abbreviations: URL, upper reference limit; hsTnI, high-sensitivity troponin I; IQR, interquartile range; CI, confidence interval; N/A, not applicable.
hsTnI 99th percentile URLs (ng/L), CV% at the URL, and proportion (%) of measurable samples above the LoD for both assays
| Assay | hsTnI 99th percentile URL (ng/L) | LoD (ng/L) | % Measurable | Assay designation | ||
|---|---|---|---|---|---|---|
|
| ||||||
| Men (CV%) | Women (CV%) | All (CV%) | ||||
| Centaur hsTnI | 15.3 (5.1%) | 11.9 (5.3%) | 13.5 (5.2%) | 2.2 | 91.5 | Level 3 (second generation, high sensitivity) |
| Atellica hsTnI | 15.5 (3.4%) | 12.9 (3.5%) | 13.4 (3.5%) | 1.3 | 93.4 | Level 3 (second generation, high sensitivity) |
URLs were determined based on AACC and AFCC guidelines. Assay designation was performed according to the proportion (%) of measurable samples (Apple, 2009 [30]).
Abbreviations: URL, upper reference limit; LoD, limit of detection; AACC, American Association for Clinical Chemistry; IFCC, International Federation of Clinical Chemistry; hsTnI, high-sensitivity troponin I.